Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edwards’ Third-Generation Sapien TAVI System Launched In Europe

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences is launching its Sapien 3 transcatheter aortic valve system in Europe following receipt of a CE mark.

You may also be interested in...

Edwards Plans To Keep ‘First-Mover’ Advantage In TAVI Against Emerging Competition

Edwards is counting on the Sapien XT valve, which will likely earn FDA approval soon, to compete with Medtronic’s recently approved CoreValve in the U.S, while in Europe the company is working quickly to upgrade customers to Sapien 3.

News Briefs: Medtronic’s CoreValve Approval; J&J Dx Unit Set For Sale; Google’s Glucometer Contact Lens

Medtronic gains FDA approval for its transcather CoreValve system months earlier than predicted. The Carlyle Group makes binding offer for J&J’s Ortho-Clinical Diagnostics business. Google is developing a wireless glucometer embedded within a contact lens. More news briefs.

Research Briefs: Edwards Starts New Sapien 3 Trial; Upper Airway Stimulator For Sleep Apnea

FDA has approved an investigational device exemption for Edwards Lifesciences’ trial of the Sapien 3 transcatheter aortic valve in intermediate-risk patients. The New England Journal of Medicine publishes results of the STAR trial of Inspire Medical’s upper airway stimulator for treatment of sleep apnea.

Related Content

Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts